Please login to the form below

Not currently logged in
Email:
Password:

Millennium expands Velcade tests

Millennium Pharmaceuticals begins tests to evaluate its blood cancer drug Velcade in combination with other drugs

Millennium Pharmaceuticals has begun tests to evaluate its blood cancer drug Velcade (bortezomib) in combination with other drugs.

Velcade, which Millennium is developing with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), can be prescribed to patients with multiple myeloma who have received at least one prior therapy.

The phase II trial will evaluate the efficacy of combining Velcade for injection with lenalidomide, dexamethasone and cyclophosphamide in the front-line multiple myeloma setting.

In a press statement, Millennium's CMO Nancy Simonian, said: "The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long term survival."

16th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...
COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....

Infographics